Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge

被引：56

作者：

van Ingen, J. ^{[1
,2
]}

Aarnoutse, R. ^{[3
]}

de Vries, G. ^{[4
,5
]}

Boeree, M. J. ^{[1
]}

van Soolingen, D. ^{[1
,2
,6
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, NL-6500 HB Nijmegen, Netherlands

[2] Natl Inst Publ Hlth & Environm, Natl TB Reference Lab, NL-3720 BA Bilthoven, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands

[4] Municipal Publ Hlth Serv, Dept TB Control, Rotterdam, Netherlands

[5] KNCV TB Fdn, The Hague, Netherlands

[6] Radboud Univ Nijmegen, Med Ctr, Dept Clin Microbiol, NL-6500 HB Nijmegen, Netherlands

来源：

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2011年 / 15卷 / 07期

关键词：

tuberculosis; multidrug-resistant; rpoB protein; Mycobacterium tuberculosis; rifampicin; DOSE RIFAMPIN;

D O I：

10.5588/ijtld.10.0127

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In an outbreak of multidrug-resistant tuberculosis, the outbreak strain had an Asp516Tyr rpoB gene mutation. Phenotypically, low-level rifampicin (RMP) resistance (minimum inhibitory concentration [MIC] 1-2 mg/l) was observed. Based on drug susceptibility test results, three patients were treated with 12-15 month rifabutin-based regimens and one with a 12-month RMP-based regimen. We retrospectively performed pharmacokinetic calculations to assess the potential for RMP treatment, from which we conclude that MICs for RMP up to 1 mu g/ml may be safely overcome by applying 20 mg/kg RMP doses in treatment regimens.

引用

页码：990 / 992

页数：3

共 15 条

[1]

de Vries G, 2005, Ned Tijdschr Geneeskd, V149, P1921

[2] Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears [J].

Diacon, A. H. ;

Patientia, R. F. ;

Venter, A. ;

van Helden, P. D. ;

Smith, P. J. ;

McIlleron, H. ;

Maritz, J. S. ;

Donald, P. R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2994-2996

[3]

ELLNER PD, 1981, SCIENCE, V246, P1575

[4] Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs [J].

Goutelle, Sylvain ;

Bourguignon, Laurent ;

Maire, Pascal H. ;

Van Guilder, Michael ;

Conte, John E., Jr. ;

Jelliffe, Roger W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) :2974-2981

[5] New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability [J].

Gumbo, Tawanda .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (04) :1484-1491

[6]

JAYARAM R, 2003, SCIENCE, V47, P2118

[7]

KRIES B, 1976, B INT UNION TUBERC, V51, P71

[8]

LONG MW, 1979, AM REV RESPIR DIS, V119, P879

[9]

National Committee for Clinical Laboratory Standards, 2003, M24A NCCLS

[10]

NUERMBERGER E, 2004, SCIENCE, V23, P243

← 1 2 →